stockportfolio.pro
Sagimet Biosciences Inc. (SGMT)
Healthcare · Biotechnology · NasdaqGM
Sagimet Biosciences Inc. revenue & earnings — last 4 fiscal years
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $0 | $2.00M | $0 | $0 |
| Gross profit | — | — | — | — |
| Net income | $-30.50M | $-27.88M | $-45.57M | $-51.04M |
| Net margin | — | -1393.8% | — | — |
Source: Sagimet Biosciences Inc. SEC filings (10-K).
Explore 4 years of Sagimet Biosciences Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track SGMT in your portfolio →
Sagimet Biosciences Inc. financial history by metric
About Sagimet Biosciences Inc.
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company's lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis, acne, and select forms of cancer. It also develops TVB-3567, a FASN inhibitor for the treatment of acne indication; and other oncology programs, such as solid tumor and glioblastoma. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
Sagimet Biosciences Inc. — frequently asked questions
What is Sagimet Biosciences Inc.'s revenue?
Sagimet Biosciences Inc. (SGMT) reported revenue of $0 for fiscal year 2025, according to its SEC filings.
Is Sagimet Biosciences Inc. profitable?
No — SGMT reported a net loss of $-51.04M in fiscal 2025.
What is SGMT's P/E ratio?
Sagimet Biosciences Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How much debt does Sagimet Biosciences Inc. have?
As of fiscal year 2025, SGMT carried roughly $0 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Sagimet Biosciences Inc.'s market cap?
Sagimet Biosciences Inc. (SGMT) has a market capitalization of about $398.30M, based on the latest data in our nightly-refreshed cache.
When does Sagimet Biosciences Inc.'s fiscal year end?
SGMT's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Sagimet Biosciences Inc.'s official SEC filings (10-K and 10-Q), covering 4 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.